GANSERT, JENNIFER LORRAINE,ANDERSON, ABRAHAM ANTONIO,GORSKI, KEVIN
申请号：
CA3057157
公开号：
CA3057157A1
申请日:
2018.04.27
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.
